

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Thomas Zeller

Page 1/16

Monday, January 25, 2021

## MAIN ARENA 1

- 13:15 – 14:10**      **LATE BREAKING TRIAL SESSION: New data and innovative concepts for treatment of femoral arteries – part I**  
*MODERATOR:*  
**Thomas Zeller**  
Sabine Steiner  
*PANEL:*  
Kenneth Rosenfield  
Marianne Brodmann
- FOCUS ON DRUG-ELUTING TECHNOLOGIES
- 13:15 – 13:20      IN.PACT global full clinical cohort: 5 year outcomes  
**Thomas Zeller**
- 13:20 – 13:25      The real-world CONSEQUENT ALL COMERS study  
Ralf Langhoff
- 13:25 – 13:30      Final long-term mortality results of paclitaxel-coated DCBs from the ILLUMENATE RCTs  
Marianne Brodmann
- 13:30 – 13:35      5 year outcomes from the IN.PACT global Asian cohort  
Young-Guk Ko
- 13:35 – 13:40      3 year outcomes of the novel KANSHAS drug-coated balloon in treatment of femoropopliteal occlusive disease: the first-in-human KANSHAS 1 study results  
Michael Lichtenberg
- 13:40 – 13:45      New safety and effectiveness data of Luminor DCB: EffPac trial 3,5 years  
Dierk Scheinert
- 13:45 – 13:50      Results of the TRANSCEND study – the randomized and controlled noninferiority trial to evaluate safety and clinical efficacy of the SurVeil™ drug-coated balloon compared to IN.PACT® Admiral® drug-coated balloon in the treatment of femoropopliteal artery disease  
Kenneth Rosenfield
- 13:50 – 13:55      2 year results from the COMPARE-trial comparing low-dose (Ranger) vs. high-dose (Impact) DCB in femoropopliteal arteries  
Sabine Steiner

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Thomas Zeller

Page 2/16

## Monday, January 25, 2021

- |               |  |
|---------------|--|
| 13:55 – 14:00 | First peripheral drug-eluting stent clinical results from China: 1 year outcomes of the Zilver PTX China study<br>Weiguo Fu                                    |
| 14:00 – 14:05 | MIMICS-3D: 2 year data from the BioMimics 3D Real world registry<br>Michael Lichtenberg  |
| 14:05 – 14:10 | The vacuum-assisted thromboaspiration in patients with acute lower limb ischaemia: safety and efficacy results from the INDIAN registry<br>Gianmarco de Donato |

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

The logo for LINC features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 3/16

Monday, January 25, 2021

## LINC STUDIO

14:10 – 14:20

### LINC Studio – LATE BREAKING TRIAL discussion

*MODERATOR:*

Dierk Scheinert

*GUEST:*

Sabine Steiner

Kenneth Rosenfield

**Thomas Zeller**

Marianne Brodmann

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Thomas Zeller

Page 4/16

Monday, January 25, 2021

## MAIN ARENA 1

14:20 – 15:05

### LATE BREAKING TRIAL SESSION: New data and innovative concepts for treatment of femoral arteries – part II

*MODERATOR:*

**Thomas Zeller**

Sabine Steiner

*PANEL:*

Brian DeRubertis

Ehrin Armstrong

Koen Deloose

#### FOCUS ON NEW DATA FOR COMPLEX LESIONS

14:20 – 14:25

IN.PACT global 4 year DCB alone vs. DCB + provisional stenting outcomes

Gunnar Tepe

14:25 – 14:30

24 month outcomes of the combination of Luminor and iVolution in 24 cm lesions: TINTIN trial

Koen Deloose

14:30 – 14:35

12 month outcomes from the Japanese post-market surveillance study of the Viabahn endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries

Osamu Iida

14:35 – 14:40

Outcomes in CLI patients treated with DCB: 4 year results from the IN.PACT global study

Michel Reijnen

14:40 – 14:45

REALITY study 12 month outcomes: safety and effectiveness of directional atherectomy followed by DCB

Brian DeRubertis

14:45 – 14:50

Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1 year outcomes for the treatment of Tosaka II and III femoropopliteal in-stent restenosis

Ehrin Armstrong

14:50 – 14:55

In-tack restenosis vs. in-stent restenosis

Raghu Kolluri

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Thomas Zeller

Page 5/16

## Monday, January 25, 2021

- |               |  |
|---------------|--|
| 14:55 – 15:00 | TORUS2 late breaking clinical trial data: preliminary 12 month results from interim analysis of the TORUS stent graft<br>Michael Lichtenberg                         |
| 15:00 – 15:05 | Fully percutaneous femoropopliteal bypass of complex PAD: population analysis and 24 month results from the DETOUR <sub>1</sub> clinical trial<br>Michael Piorkowski |

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

The logo for LINC (Leipzig Interventional Course) features the letters 'L I N C' in a bold, blue, sans-serif font. The letters are partially overlaid by a thick, blue, brush-stroke-like graphic that curves from the bottom left towards the top right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 6/16

Tuesday, January 26, 2021

## MAIN ARENA 1

- 08:13 – 09:00**     **LINC 2021 CONNECT - China: “Leave nothing behind” – advanced treatment concepts for complex lesions – part II**  
*CHAIRMAN:*  
Wei Guo  
*MODERATOR:*  
Dierk Scheinert  
**Thomas Zeller**
- 08:13 – 08:19     DES vs. DCB+BMS are they the same? Insights from the REACT study  
Koen Deloose
- 08:19 – 08:48     Live case transmission from Leipzig  
Universitätsklinikum Leipzig, Abt. Angiologie - Live case center
- 08:48 – 08:54     The transition from open endarterectomy to interventional treatment of the CFA – how far have we come?  
Martin Malina
- 08:54 – 09:00     Interventional treatment of the common femoral artery – update on the PESTO trial  
**Thomas Zeller**

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC

The logo for LINC features the letters 'LINC' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 7/16

Tuesday, January 26, 2021

## LINC STUDIO

15:00 – 15:05

### LINC Studio – Is debulking a valid concept?

*MODERATOR:*

Dierk Scheinert

*GUEST:*

Giancarlo Biamino

**Thomas Zeller**

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Thomas Zeller

Page 8/16

Tuesday, January 26, 2021

## MAIN ARENA 1

- 15:05 – 16:35**     **SYMPOSIUM: The reality of PAD and calcium: treatment strategies for improved outcomes**  
supported by Medtronic  
*MODERATOR:*  
Dierk Scheinert  
*PANEL:*  
**Thomas Zeller**  
Giovanni Torsello  
Ravish Sachar  
Ralf Langhoff
- 15:05 – 16:05     Live case transmission from Leipzig  
Universitätsklinikum Leipzig, Abt. Angiologie - Live case center
- 16:05 – 16:09     Redefining the management of PAD: a critical look at calcium  
Ralf Langhoff
- 16:09 – 16:13     Clinical evidence for vessel preparation followed by DCB in the most challenging lesions  
Ravish Sachar
- 16:13 – 16:17     Panel discussion
- 16:17 – 16:21     DCB after vessel prep: what is the clinical evidence for long-term effectiveness of DCB to reduce  
reinterventions?  
Giovanni Torsello
- 16:21 – 16:33     Additional strategies, tools and techniques for peripheral vascular therapies: a pre-recorded case  
**Thomas Zeller**
- 16:33 – 16:35     Closing remarks

We are asking all faculty members to strictly respect the given time limits.



# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 9/16

Wednesday, January 27, 2021

## MAIN ARENA 2

- 12:30 – 13:15**      **LUNCH SYMPOSIUM: LINC and LEARN: the consistency of intravascular lithotripsy (IVL) across multiple vessel beds**  
supported by Shockwave  
*MODERATOR:*  
**Thomas Zeller**  
*PANEL:*  
Arne Schwindt  
Francesco Liistro  
George Adams
- 12:30 – 12:35      Introduction, IVL mechanism of action, and historical perspective  
**Thomas Zeller**
- 12:35 – 12:45      Insights from the DISRUPT PAD III RCT in severely calcified fempop lesions  
Arne Schwindt
- 12:45 – 12:55      DISRUPT PAD III observational study – below-the-knee subset  
George Adams
- 12:55 – 13:05      IVL – a reliable and efficacious vessel preparation strategy  
Francesco Liistro
- 13:05 – 13:15      Q&A, discussion, and conclusion

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC



Thomas Zeller

Page 10/16

Wednesday, January 27, 2021

## LINC STUDIO

13:15 – 13:30

**LINC Studio – The challenge of thrombotic and embolic lesions: do we need specific strategies?**

*MODERATOR:*

Dierk Scheinert

Sabine Steiner

*GUEST:*

Andrej Schmidt

**Thomas Zeller**

Jos van den Berg

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC

The logo features the letters 'LINC' in a bold, blue, sans-serif font. A thick, dark blue brushstroke is drawn across the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 11/16

Wednesday, January 27, 2021

## LINC STUDIO

13:45 – 13:55

### LINC Studio – What is best for in-stent-restenosis?

*MODERATOR:*

Dierk Scheinert

Sabine Steiner

*GUEST:*

Andrej Schmidt

**Thomas Zeller**

Koen Deloose

Aloke Finn

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Thomas Zeller

Page 12/16

Wednesday, January 27, 2021

## MAIN ARENA 1

- 15:15 – 16:30**      **SYMPOSIUM: How predictability and evidence lead to proven patient outcomes**  
supported by Cook Medical  
*MODERATOR:*  
Michael Dake  
*PANEL:*  
**Thomas Zeller**  
Carlos Mena-Hurtado  
Aloke Finn  
Michel Bosiers
- 15:15 – 15:25      When the benefit of paclitaxel outweigh the risk  
**Thomas Zeller**
- 15:25 – 15:35      Prediction model for freedom from TLR from a multi-study analysis of long-term results with the Zilver PTX stent  
Michael Dake
- 15:35 – 15:45      How the prediction model impact my daily clinical practice  
Carlos Mena-Hurtado
- 15:45 – 16:15      Live case transmission from Leipzig  
Universitätsklinikum Leipzig, Abt. Angiologie - Live case center
- 16:15 – 16:20      Pre-clinical impact of Eluvia  
Aloke Finn
- 16:20 – 16:25      Clinical impact of Eluvia  
Michel Bosiers
- 16:25 – 16:30      Q&A, discussion, and conclusion

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC



Thomas Zeller

Page 13/16

Wednesday, January 27, 2021

## LINC STUDIO

16:30 – 16:45

### LINC Studio – The challenge of vessel calcification

*MODERATOR:*

Dierk Scheinert

Sabine Steiner

*GUEST:*

Aloke Finn

**Thomas Zeller**

Andrej Schmidt

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC

The logo for LINC features the letters 'LINC' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element is positioned behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 14/16

Wednesday, January 27, 2021

## LINC STUDIO

18:45 – 19:00

**LINC Studio – Current practice with drug-eluting devices**

*MODERATOR:*

Dierk Scheinert

Sabine Steiner

*GUEST:*

**Thomas Zeller**

Andrej Schmidt

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Thomas Zeller

Page 15/16

Wednesday, January 27, 2021

## MAIN ARENA 1

- 19:00 – 20:20**    **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**  
*MODERATOR:*  
Dierk Scheinert  
Peter Schneider  
*PANEL:*  
Andrew Holden  
Marianne Brodmann  
Robert Lookstein
- 19:00 – 19:03    Introduction by the moderators  
Dierk Scheinert  
Peter Schneider
- 19:03 – 19:08    Insights on paclitaxel safety from the femoral-popliteal RCTs  
Peter Schneider
- 19:08 – 19:13    Insights on paclitaxel safety from femoral-popliteal real-world data  
Eric Secemsky
- 19:13 – 19:21    New insights from the interim safety analysis of the SWEDEPAD study  
Joakim Nordanstig
- 19:21 – 19:26    How does the Voyager data help us understand the risks of paclitaxel?  
Marc Bonaca
- 19:26 – 19:31    Paclitaxel safety in patients with CLTI  
Marianne Brodmann
- 19:31 – 19:36    Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications  
Robert Lookstein
- 19:36 – 19:41    New data on paclitaxel in the next couple of years; what should we expect?  
Eva Freisinger
- 19:41 – 19:49    Panel discussion

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Thomas Zeller

Page 16/16

## Wednesday, January 27, 2021

- |               |   |
|---------------|---|
| 19:49 – 19:54 | Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?<br>Sahil Parikh  |
| 19:54 – 19:59 | Previous experience with limus compounds in the non-coronary arteries; lessons learned<br><b>Thomas Zeller</b>  |
| 19:59 – 20:04 | New limus delivering devices for above and below knee occlusive disease; when to expect results?<br>Andrew Holden   |
| 20:04 – 20:14 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?<br>Dierk Scheinert |
| 20:14 – 20:20 | Panel discussion  |

We are asking all faculty members to strictly respect the given time limits.